The goal of this project is to identify and validate interstitial cystitis/painful bladder syndrome (IC/PBS)- associated urinary metabolites. IC/PBS is a debilitating condition that presents with a constellation of symptoms including bladder pain, urinary urgency, frequency, nocturia, and small voided volumes in the absence of other identifiable etiologies. The diagnosis of IC/PBS remains dependent on subjective parameters, leading to extreme difficulties in accurately phenotyping patients. Our central hypothesis is that IC/PBS- associated metabolites in the urine of IC/PBS patients can segregate patients from control subjects, and that their levels are correlated with clinical symptoms. This hypothesis is based on our proton nuclear magnetic resonance (NMR) spectroscopy findings identifying urine metabolites that appear to stratify IC/PBS patients from healthy controls. We propose to substantially build on these results and determine whether candidate urine metabolites are diagnostic indicators of IC/PBS. To test this hypothesis we will (Aim 1) Identify IC/PBS-associated metabolites in urine using two independent platforms, proton NMR spectroscopy and quadrupole time-of-flight (Q-TOF) mass spectrometry. We will determine whether candidate metabolites segregate IC/PBS patients from control subjects, and are associated with clinical severity, including chronic bladder pain. In order to achieve a deeper understanding of the underlying biological nature of this condition, we will identify pathologic networks associated with IC/PBS using integrative bioinformatics. We will also (Aim 2) create a Cedars-Sinai Medical Center IC/PBS urine biorepository and will conduct preliminary validation studies of IC/PBS metabolites. Our long-term goals include the identification of diagnostic urinary biomarkers that can serve as non-invasive and accurate means of diagnosing IC/PBS and stratifying these patients from patients with other bladder or pelvic floor conditions. We also seek in the long term to validate molecular targets for therapeutic strategies. This study has a significant potential clinical impact because results may lead to clinical methods to increase diagnostic accuracy and an improved understanding of the molecular basis of IC/PBS and its relationship to urologic conditions with overlapping symptoms.

Public Health Relevance

Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition that presents with a constellation of symptoms including bladder pain, urinary urgency, frequency, nocturia, and small voided volumes in the absence of other identifiable etiologies. A lack of objective diagnostic criteria has affected our ability to adequaely treat the disease. The goal of this proposed study is to identify/validate sensitive and non- invasive diagnostic biomarkers using urine specimens that stratify IC/PBS patients from healthy subjects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK100974-01
Application #
8627861
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O2))
Program Officer
Kirkali, Ziya
Project Start
2013-09-27
Project End
2014-09-26
Budget Start
2013-09-27
Budget End
2014-09-26
Support Year
1
Fiscal Year
2013
Total Cost
$416,294
Indirect Cost
$166,294
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Ha, Yun-Sok; Kim, Yeon-Yong; Yu, Na Hee et al. (2018) Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway. Investig Clin Urol 59:263-274
Mansour, Ahmed M; Abdelrahim, Mona; Laymon, Mahmoud et al. (2018) Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer. BMC Urol 18:100
Shahid, Muhammad; Gull, Nicole; Yeon, Austin et al. (2018) Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. Sci Rep 8:4505
Yeon, Austin; You, Sungyong; Kim, Minhyung et al. (2018) Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics 8:4520-4534
Shahid, Muhammad; Lee, Min Young; Yeon, Austin et al. (2018) Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. Sci Rep 8:10859
Jung, Jae Hun; You, Sungyong; Oh, Jae Won et al. (2018) Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Lett 437:1-12
Moon, Ju-Yeun; Choi, Man Ho; Kim, Jayoung (2016) Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocr Relat Cancer 23:R455-67
Kind, Tobias; Cho, Eunho; Park, Taeeun D et al. (2016) Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. Sci Rep 6:39227
Chen, Zhaohui; Kim, Jayoung (2016) Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol 16:11
Kim, Jayoung (2016) Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol 57 Suppl 1:S98-S105

Showing the most recent 10 out of 21 publications